OBJECTIVE:Women who become pregnant during the conduct of biomedical human immunodeficiency virus prevention trials are taken off the study product for safety reasons. High pregnancy rates can compromise statistical integrity in these trials. The comprehensive contraceptive curriculum developed for the Centre for the AIDS Programme of Research in South Africa (CAPRISA) 004 trial was evaluated for its ability to enhance contraceptive uptake, reduce pregnancy rates, and preserve statistical integrity. METHODS: Contraceptive- and pregnancy-related eligibility criteria were specified in the protocol. We enrolled women who opted for a nonbarrier method of contraceptive and provided hormonal contraceptives onsite at no cost. At each monthly study visit, we provided pregnancy prevention counseling and performed pregnancy testing. Study product was withheld on pregnancy diagnosis, but women continued with monthly follow-up. RESULTS: Contraceptive use was high throughout the study with 100% uptake at baseline and 94.71% use after a mean of 18 months follow-up at exit. Injectable progestins, particularly medroxyprogesterone acetate, remained the preferred choice of contraceptive. After 30 months of follow-up, 54 pregnancies were reported out of 889 participants, giving a pregnancy incidence rate of 3.95 per 100 woman-years (95% confidence interval 2.96-5.17). Of all pregnancies, two thirds (64.81%) resulted in a full-term live birth, whereas 18.52% and 11.11% pregnancies culminated as miscarriage and terminated pregnancies, respectively. There were no congenital anomalies in the early neonatal period. Pregnancies resulted in 1.56% of woman-years of study follow-up lost as a result of temporary product withdrawal. CONCLUSION: The CAPRISA 004 contraceptive curriculum was an effective strategy for maintaining low pregnancy rates, thereby minimizing product withdrawal and loss of follow-up time. LEVEL OF EVIDENCE: III.
RCT Entities:
OBJECTIVE:Women who become pregnant during the conduct of biomedical human immunodeficiency virus prevention trials are taken off the study product for safety reasons. High pregnancy rates can compromise statistical integrity in these trials. The comprehensive contraceptive curriculum developed for the Centre for the AIDS Programme of Research in South Africa (CAPRISA) 004 trial was evaluated for its ability to enhance contraceptive uptake, reduce pregnancy rates, and preserve statistical integrity. METHODS: Contraceptive- and pregnancy-related eligibility criteria were specified in the protocol. We enrolled women who opted for a nonbarrier method of contraceptive and provided hormonal contraceptives onsite at no cost. At each monthly study visit, we provided pregnancy prevention counseling and performed pregnancy testing. Study product was withheld on pregnancy diagnosis, but women continued with monthly follow-up. RESULTS: Contraceptive use was high throughout the study with 100% uptake at baseline and 94.71% use after a mean of 18 months follow-up at exit. Injectable progestins, particularly medroxyprogesterone acetate, remained the preferred choice of contraceptive. After 30 months of follow-up, 54 pregnancies were reported out of 889 participants, giving a pregnancy incidence rate of 3.95 per 100 woman-years (95% confidence interval 2.96-5.17). Of all pregnancies, two thirds (64.81%) resulted in a full-term live birth, whereas 18.52% and 11.11% pregnancies culminated as miscarriage and terminated pregnancies, respectively. There were no congenital anomalies in the early neonatal period. Pregnancies resulted in 1.56% of woman-years of study follow-up lost as a result of temporary product withdrawal. CONCLUSION: The CAPRISA 004 contraceptive curriculum was an effective strategy for maintaining low pregnancy rates, thereby minimizing product withdrawal and loss of follow-up time. LEVEL OF EVIDENCE: III.
Authors: Quarraisha Abdool Karim; Salim S Abdool Karim; Janet A Frohlich; Anneke C Grobler; Cheryl Baxter; Leila E Mansoor; Ayesha B M Kharsany; Sengeziwe Sibeko; Koleka P Mlisana; Zaheen Omar; Tanuja N Gengiah; Silvia Maarschalk; Natasha Arulappan; Mukelisiwe Mlotshwa; Lynn Morris; Douglas Taylor Journal: Science Date: 2010-07-19 Impact factor: 47.728
Authors: Elizabeth G Raymond; Douglas Taylor; Willard Cates; Elizabeth E Tolley; David Borasky; Aida Cancel; Benoit Masse; Elizabeth A Bukusi; Brooke R Johnson Journal: Sex Transm Dis Date: 2007-12 Impact factor: 2.830
Authors: Quarraisha Abdool Karim; Ayesha B M Kharsany; Janet A Frohlich; Lise Werner; May Mashego; Mukelisiwe Mlotshwa; Bernadette T Madlala; Fanelesibonge Ntombela; Salim S Abdool Karim Journal: Int J Epidemiol Date: 2010-11-03 Impact factor: 7.196
Authors: Lut Van Damme; Roshini Govinden; Florence M Mirembe; Fernand Guédou; Suniti Solomon; Marissa L Becker; B S Pradeep; A K Krishnan; Michel Alary; Bina Pande; Gita Ramjee; Jennifer Deese; Tania Crucitti; Doug Taylor Journal: N Engl J Med Date: 2008-07-31 Impact factor: 91.245
Authors: Koen K A Van Rompay; Lucie Durand-Gasselin; Laurie L Brignolo; Adrian S Ray; Kristina Abel; Tomas Cihlar; Abigail Spinner; Christopher Jerome; Joseph Moore; Brian P Kearney; Marta L Marthas; Hans Reiser; Norbert Bischofberger Journal: Antimicrob Agents Chemother Date: 2008-06-23 Impact factor: 5.191
Authors: Brandon L Guthrie; Andrea Introini; Alison C Roxby; Robert Y Choi; Rose Bosire; Barbara Lohman-Payne; Taha Hirbod; Carey Farquhar; Kristina Broliden Journal: J Acquir Immune Defic Syndr Date: 2015-05-01 Impact factor: 3.731
Authors: Daniel Westreich; Naiomi Jamal; Jennifer S Smith; Doreen Schulze; Sophie Williams; Pam Michelow; Simon Levin; Cynthia Firnhaber Journal: Contraception Date: 2014-01-07 Impact factor: 3.375
Authors: Carolyne A Akello; Katherine E Bunge; Clemensia Nakabiito; Brenda G Mirembe; Mary Glenn Fowler; Anupam Mishra; Jeanne Marrazzo; Zvavahera M Chirenje; Connie Celum; Jennifer E Balkus Journal: J Womens Health (Larchmt) Date: 2017-02-17 Impact factor: 2.681
Authors: Connie Celum; Jared M Baeten; James P Hughes; Ruanne Barnabas; Albert Liu; Heidi Van Rooyen; Susan Buchbinder Journal: J Acquir Immune Defic Syndr Date: 2013-07 Impact factor: 3.731